i det mindste ser det ud til at arzerra+alkylator slår ibrutinib som monoterapi - http://www.prnewswire.com/news-releases/ibrutinib-data-published-in-the-lancet-oncology-suggest-a-positive-effect-in-previously-untreated-chronic-lymphocytic-leukemia-patients-over-age-65-235149691.html